Editorial |

Basal Cell Carcinoma:  Still an Enigma

Joyce A. Leman, MRCP(UK); Pamela M. McHenry, MD, MRCP(UK)
Arch Dermatol. 2001;137(9):1239-1240. doi:10.1001/archderm.137.9.1239.
Text Size: A A A
Published online


IT IS SOMETIMES a paradox in medicine that rare conditions are intensively studied, while common conditions are often overlooked. Such has been the case with basal cell carcinoma (BCC). The public health burden of BCC is considerable, yet the profile afforded to this cutaneous malignancy is low. This is surprising, as BCC is the most common human cancer.1 It may be a reflection of the fact that BCC has a very low mortality rate. Using mortality rates as a measure of the importance of BCC in a population, however, will grossly underestimate its importance. Morbidity from this skin cancer is considerable in terms of cosmetic and functional outcome. Increasing numbers of younger individuals are being affected, and treatment consumes considerable medical resources. Morbidity is likely to increase, as, in the white population of North America, the incidence rate of BCC has doubled approximately every 14 years.2 Incidence figures for BCC are likely to be underestimates, as many lesions are treated without histological confirmation, but figures quoted for males and females range from 175 and 124 per 100 000 in Minnesota3 to 849 and 605 per 100 000, respectively, in Australia.4

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 12

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles